Price T Rowe Associates Inc Elevation Oncology, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 16,841 shares of ELEV stock, worth $10,273. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,841Holding current value
$10,273% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ELEV
# of Institutions
81Shares Held
52MCall Options Held
700Put Options Held
2.1K-
Logos Global Management LP San Francisco, CA3.85MShares$2.35 Million0.98% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.6MShares$2.2 Million0.05% of portfolio
-
Tang Capital Management LLC San Diego, CA3.06MShares$1.87 Million1.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA2.96MShares$1.8 Million0.47% of portfolio
-
Aisling Capital Management LP New York, NY2.83MShares$1.73 Million3.35% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $14.2M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...